# Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy

> **NCT02448329** · PHASE2 · COMPLETED · sponsor: **Samsung Medical Center** · enrollment: 26 (actual)

## Conditions studied

- Advanced Gastric Adenocarcinoma

## Interventions

- **DRUG:** AZD1775
- **DRUG:** paclitaxel

## Key facts

- **NCT ID:** NCT02448329
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-14
- **Primary completion:** 2019-12
- **Final completion:** 2021-04-19
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2022-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02448329

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02448329, "Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02448329. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*